Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio
Shots:
- Pfizer acquires Therachon- in all stock transaction for $810M. Therachon to receive $340M upfront with additional payment on milestones of development and commercialization of its TA-46 candidate targeted for achondroplasia
- Additionally- Therachon to spin-off its apraglutide development program into an independent firm- prior closure of the transaction. Pfizer Ventures to hold an equity stake in the new firm
- TA-46 is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy has completed its P-I for achondroplasia and has received EMA’s and FDA’s ODD. Apraglutide is a qw GLP-2 analog P-II candidate targeted for short bowel syndrome
Click here to read full press release/ article | Ref: Pfizer | Image: Twitter
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com